HAVCR2 and neoplasm: A variety of other combinations with immune inhibition [such as with LAG-3, TIM-3, BTLA, etc.], chemotherapeutic agents and irradiation—as additive or designed to make a tumor more “antigenic”, etc., are in the drawing board.